{"entity":{"id":"azd4512","kind":"drug","name":"AZD4512","aka":[],"tldr":"AZD4512 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for hodgkin lymphoma, aimed at CD22.","summary":"AZD4512 is an antibody-drug conjugate developed by AstraZeneca. Its target is CD22 (the sponsor names CD22). The sponsor states: An antibody-drug conjugate targeting CD22, administered by intravenous infusion; specific payload/mechanism detail beyond CD22 targeting was not stated on the fetched page. ClinicalTrials.gov describes the intervention as: AZD4512 is an antibody-drug conjugate targeting cluster of differentiation 22 (CD22) that will be administered via IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07123454, plans to enrol 91 participants with primary completion expected 2028-03-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AZD4512","url":"https://clinicaltrials.gov/search?intr=AZD4512"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["cd22"],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07123454","nct07109219"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"An antibody-drug conjugate targeting CD22, administered by intravenous infusion; specific payload/mechanism detail beyond CD22 targeting was not stated on the fetched page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd4512/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct07123454","kind":"trial","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","route":"/trials/nct07123454/"},{"id":"nct07109219","kind":"trial","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","route":"/trials/nct07109219/"}]}}